Insulin Lispro-Aabc
Injection · trading as Lyumjev Tempo Pen
To Be Discontinued Active (discontinuing) — Day 202
High impact — Sole-source drug with no supply currently available from this manufacturer.
FDA shortage record
- Substance
- Insulin Lispro-Aabc
- Brand name
- Lyumjev Tempo Pen
- Manufacturers / suppliers
-
- Eli Lilly and Company
- Eli Lilly and Co.
- Dosage form
- Injection
- Presentation
- Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)
- Route(s)
- SUBCUTANEOUS
- Therapeutic category
- Endocrinology/Metabolism
- Package NDC
0002-8235-99- Initially posted
- 10/24/2025
- Days on shortage list
- 202
- Discontinued
- 10/24/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 1 record for Insulin Lispro-Aabc
Reason and context
A business decision was made to discontinue manufacture of the drug.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-545-5979.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
c5a056e2-b568-4ca6-9ed8-79c010942d00). - FDA UNII identifier:
GFX7QIS1II. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.